A liquid biopsy can be used for molecular characterization of the tumor and its non-invasive nature allows repeat sampling to monitor genetic changes over time without the need for a tissue biopsy. According to market research study published by Gen Consulting Company, the global non-invasive liquid biopsy market stood at around USD 1,467 million in 2020 and is projected to rise to a worth of USD 4,072 million by 2027 end, thereby garnering a CAGR of 15.7% during 2021-2027.
The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global non-invasive liquid biopsy market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the non-invasive liquid biopsy industry.
The non-invasive liquid biopsy market is segmented on the basis of product, technology, sample, application, and application. The non-invasive liquid biopsy market is segmented as below:
By product:
– kits and assays
– services
By technology:
– polymerase chain reaction (PCR)
– sequencing
– microarray
– others
By sample:
– faeces
– urine
– saliva
– others
By application:
– application
– oncology
– reproductive health
– metabolic disorders
– others
By region:
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
The report explores the recent developments and profiles of key vendors in the Global Non-Invasive Liquid Biopsy Market, including Analytik Jena AG, EXACT Sciences Corporation, Exosome Diagnostics, Inc. (Bio-Techne Corporation), Lonza Group AG (Exosomics Siena S.p.A), MDxHealth BV, Merck KGaA, OraSure Technologies, Inc., PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Historical & Forecast Period
This research report provides analysis for each segment from 2017 to 2027 considering 2020 to be the base year.
Scope of the Report
– To analyze and forecast the market size of the global non-invasive liquid biopsy market.
– To classify and forecast the global non-invasive liquid biopsy market based on product, technology, sample, application, and application.
– To identify drivers and challenges for the global non-invasive liquid biopsy market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global non-invasive liquid biopsy market.
– To identify and analyze the profile of leading players operating in the global non-invasive liquid biopsy market.
Why Choose This Report
– Gain a reliable outlook of the global non-invasive liquid biopsy market forecasts from 2021 to 2027 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Base Year | 2020 |
| Forecast Year | 2021-2027 |
| CAGR (2021-2027) | 5.4% |
| Pages | 85 |
| Key Players | Abbott Laboratories, ARKRAY Inc., Becton Dickinson and Company, bioMerieux S.A., Lionex Gmbh, Oxford Immunotec Global PLC, Qiagen N.V. |
The global dental burs market is projected to expand at a CAGR of ~5.6 percent across the forecast period of 2024 – 2030, according to the latest edition of the…
The global urology laser market is estimated to increase at the rate of 5.6% each year in the period from 2023 to 2029. Urology lasers are medical devices specifically designed…
The global scar management market, in terms of revenue, is anticipated to progress at a CAGR of 5.8% during the forecast period, 2023-2029. Scar management encompasses various techniques and treatments…
Please fill out our form and we will get back to you.
